Related references
Note: Only part of the references are listed.TSA-induced DNMT1 down-regulation represses hTERT expression via recruiting CTCF into demethylated core promoter region of hTERT in HCT116
Jee-Hye Choi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents
Katherine M. Moxley et al.
ONCOLOGIST (2010)
Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications
David S. Schrump
CLINICAL CANCER RESEARCH (2009)
Histone deacetylase inhibitors:: mechanism of action and therapeutic use in cancer
Olaia Martinez-Iglesias et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2008)
Histone deacetylase inhibitors in cancer therapy
Min-Jung Lee et al.
CURRENT OPINION IN ONCOLOGY (2008)
Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1
Leslie G. Wooten-Blanks et al.
FASEB JOURNAL (2007)
Site-specific methylation of CpG nucleotides in the hTERT promoter region can control the expression of hTERT during malignant progression of colorectal carcinoma
Jee-Hye Choi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells
Hyun Joo Woo et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2007)
hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway
C. Massard et al.
ONCOGENE (2006)
Inhibition of telomerase enhances apoptosis induced by sodium butyrate via mitochondrial pathway
L. Xi et al.
APOPTOSIS (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer
J Murakami et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Telomerase: a potential therapeutic target for cancer
TM Fletcher
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells
M Folini et al.
EUROPEAN JOURNAL OF CANCER (2005)
Telomeres, telomerase, and apoptosis
C Mondello et al.
BIOCHEMISTRY AND CELL BIOLOGY (2004)
Unusual distribution of DNA methylation within the hTERT CpG island in tissues and cell lines
I Guilleret et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction
LW Elmore et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Telomerase activity and human telomerase reverse transcriptase mRNA expression are correlated with clinical aggressiveness in soft tissue tumors
R Tomoda et al.
CANCER (2002)
Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells
M Suenaga et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer
H Hara et al.
LUNG CANCER (2001)
Share Paper
